[INQ. NO. 2106C10] Korea United Pharm has 40 anti-cancer products, the largest number among domestic companies. Meeting the ASEAN GMP and PIC/S GMP standards, it provides qualified and affordable products that are suitable for the brand generic market.
Cilostan CR Tab (Cilostazol 200mg) is effective in improvement of ischemic symptoms such as ulcers, pain, and anaphrodisia due to chronic arterial occlusion (Burger’s disease, occlusive arteriosclerosis, diabetic peripheral vasculopathy, etc.) and inhibiting recurrence of cerebral infarction (except for cardiogenic cerebral embolism).
Clanza CR Tab (Aceclofenac 200mg) is effective for chronic musculoskeletal pain such as rheumatoid arthritis and osteoarthritis (degenerative arthritis). By using the patented CR formulation method, it features quick and 24-hour lasting effects.
Clavixin Duo Cap (Clopidogrel 75mg, Aspirin 100mg) is effective in improving atherosclerotic symptoms (cardiovascular death, myocardial infarction, stroke or refractory ischemia) in patients with acute coronary syndrome. The main ingredient is separated into the immediate-release layer and the enteric layer to maximize stability by blocking interactions between the active ingredients.
Gastiin CR Tab (Mosapride 15mg) is effective in digestive symptoms (heartburn, nausea, vomiting) due to functional dyspepsia. It separates the immediate-release layer and the sustained-release layer to enable rapid effect and sustained action for 24 hours at the same time.
Founded in 1987, Republic of Korea United Pharm Inc. is a manufacturer of specialty medicines. Since its inception, the company has focused on overseas markets and established local factories in Vietnam, Egypt, and the United States. Having branches in Vietnam, Philippines, Myanmar, Indonesia, and other major countries, it is growing into a multinational pharmaceutical company it has aspired to be. Based on R&D investment of more than 13% of sales, Republic of Korea United Pharm has become the top-ranked research-oriented pharmaceutical company in Korea and has launched six new improved drugs by focusing on the development of Incrementally Modified Drugs (IMDs). In particular, the improved new drug Silosan CR achieved remarkable sales of 20 billion units in 2016 alone as a single product.
Korean-Products.com | Blog Magazine of Korean products, brands and Goods